{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3164, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de073-7b6a-72bb-8d98-812d56d63617", "docSlug": "f8b2787992eb3375620f74057447d0c9", "documentTitle": "Aravive | Investor Presentation Deck | 39 slides", "authorId": "aravive", "authorName": "Aravive", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "appendix_data", "function": "summarize", "notes": "Data as of 6/30/2022.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/37", "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617", "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7b6a-72bb-8d98-812d56d63617", "docSlug": "f8b2787992eb3375620f74057447d0c9", "documentTitle": "Aravive | Investor Presentation Deck | 39 slides", "authorId": "aravive", "authorName": "Aravive", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "mission", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/38", "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617", "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7b6a-72bb-8d98-812d56d63617", "docSlug": "f8b2787992eb3375620f74057447d0c9", "documentTitle": "Aravive | Investor Presentation Deck | 39 slides", "authorId": "aravive", "authorName": "Aravive", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/39", "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617", "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Features a photo of a child named Albie living with LAL-D.", "imagePath": "https://imgproxy.kitesheet.com/2pRoNCoAQtc8OakwMt7xUQMkfhgfGtOcPIzRPqCF7dc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wYzM1YjQxY2RiYjgwNTI2ZTFhYjgyMmJmMDhmOWE3ZS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/1", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "002044da-5f3d-4c5d-87d7-00f423a64de2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The document provides an overview of the rare disease landscape and AstraZeneca's strategy", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/NdCIlRkoZ2vCUm8OgTJ7IFqMZM1KMm2Zz6Ex0n_WTow/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wYzM1YjQxY2RiYjgwNTI2ZTFhYjgyMmJmMDhmOWE3ZS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/yVso3x09PurNy79fQfSL5NeGxVtBhKE-6RdzNpgtQ5E/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wYzM1YjQxY2RiYjgwNTI2ZTFhYjgyMmJmMDhmOWE3ZS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/fgCE-DTvt-mM2wY5vYczXwx2JXqFQyUOEU7LjA2FL78/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wYzM1YjQxY2RiYjgwNTI2ZTFhYjgyMmJmMDhmOWE3ZS9wMDAxLnBuZw" }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/2", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "002044da-5f3d-4c5d-87d7-00f423a64de2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The document provides an overview of the rare disease landscape and AstraZeneca's strategy", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "agenda", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/3", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "002044da-5f3d-4c5d-87d7-00f423a64de2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The document provides an overview of the rare disease landscape and AstraZeneca's strategy", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/4", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "002044da-5f3d-4c5d-87d7-00f423a64de2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The document provides an overview of the rare disease landscape and AstraZeneca's strategy", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "key_messages", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/5", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-5", "loopMatches": [ { "to": 9, "from": 5, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "16c2829b-de3c-46e3-baae-e807d4712dd1", "evidence": "The document uses a golden circle framework to explain the company's strategy and value proposition", "position": 0, "objective": "Why AstraZeneca's Rare Disease strategy matters", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "497e0c2f-3e92-48c5-90a0-a4236f187c36", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document highlights the limitations of current treatment options and the need for new medicines", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "executive_summary", "function": "establish_context", "notes": "The slide uses iconography to represent key statistics about rare diseases.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/6", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-6", "loopMatches": [ { "to": 9, "from": 5, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "16c2829b-de3c-46e3-baae-e807d4712dd1", "evidence": "The document uses a golden circle framework to explain the company's strategy and value proposition", "position": 0, "objective": "Why AstraZeneca's Rare Disease strategy matters", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "497e0c2f-3e92-48c5-90a0-a4236f187c36", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document highlights the limitations of current treatment options and the need for new medicines", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "key_messages", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/7", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-7", "loopMatches": [ { "to": 9, "from": 5, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "16c2829b-de3c-46e3-baae-e807d4712dd1", "evidence": "The document uses a golden circle framework to explain the company's strategy and value proposition", "position": 0, "objective": "Why AstraZeneca's Rare Disease strategy matters", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "497e0c2f-3e92-48c5-90a0-a4236f187c36", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document highlights the limitations of current treatment options and the need for new medicines", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "other", "function": "establish_context", "notes": "The slide uses a visual mapping of products to indications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/8", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-8", "loopMatches": [ { "to": 9, "from": 5, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "16c2829b-de3c-46e3-baae-e807d4712dd1", "evidence": "The document uses a golden circle framework to explain the company's strategy and value proposition", "position": 0, "objective": "Why AstraZeneca's Rare Disease strategy matters", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "497e0c2f-3e92-48c5-90a0-a4236f187c36", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document highlights the limitations of current treatment options and the need for new medicines", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a horizontal bar chart format to represent clinical trial progress.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/9", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-9", "loopMatches": [ { "to": 9, "from": 5, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "16c2829b-de3c-46e3-baae-e807d4712dd1", "evidence": "The document uses a golden circle framework to explain the company's strategy and value proposition", "position": 0, "objective": "Why AstraZeneca's Rare Disease strategy matters", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "497e0c2f-3e92-48c5-90a0-a4236f187c36", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document highlights the limitations of current treatment options and the need for new medicines", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "transition", "function": "transition", "notes": "The slide uses a human-centric image to transition into a business section about medical leadership.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/10", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-10", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "roadmap", "function": "present_solution", "notes": "The slide uses a matrix-like layout to map drug candidates against biological targets and development status.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/11", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-11", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "propose_solution", "function": "present_framework", "notes": "The slide uses a biological process flow to explain the therapeutic rationale for C5 inhibition.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/12", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-12", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "other", "function": "present_solution", "notes": "The slide uses a timeline-like arrow to represent innovation and expansion into new indications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/13", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-13", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "key_messages", "function": "summarize", "notes": "The slide uses a waterfall-style comparison for pricing and a 2x2 grid for indication-specific growth strategies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/14", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-14", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "key_messages", "function": "analyze_data", "notes": "Includes clinical trial data (Study 301) and registry survival analysis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/15", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-15", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "key_takeaways", "function": "summarize", "notes": "HLR = high-level results; gMG = generalised myasthenia gravis; MG-ADL = myasthenia gravis activities of daily living; QMG = quantitative myasthenia gravis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/16", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-16", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "key_takeaways", "function": "analyze_data", "notes": "Includes three distinct data visualizations: a bar chart for median MG-ADL, a box plot for change from baseline, and a line chart for mean MG-ADL over time.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/17", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-17", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "key_takeaways", "function": "analyze_data", "notes": "Includes 'Number at risk' table below the x-axis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/18", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-18", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "key_messages", "function": "quantify_opportunity", "notes": "The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/19", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-19", "loopMatches": [ { "to": 19, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b", "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs", "position": 1, "objective": "How AstraZeneca's pipeline addresses high unmet medical needs", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 19, "from": 10, "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses a combination of a timeline/map graphic and a bar chart to demonstrate market penetration and adoption speed.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/20", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-20", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "propose_solution", "function": "present_solution", "notes": "Comparison of molecular weight (25 kDa vs 150 kDa) and administration method.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/21", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-21", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "problem_statement", "function": "diagnose_problem", "notes": "Includes clinical trial design diagram for Part A and Part B.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/22", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-22", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "propose_solution", "function": "present_solution", "notes": "Includes a biological pathway diagram and a comparison of circulating concentrations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/23", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-23", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a horizontal timeline-like structure to compare three drug candidates (ALXN2040, ALXN2050, ALXN2080).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/24", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-24", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "key_takeaways", "function": "summarize", "notes": "Includes FDA Breakthrough Designation callout and trial design diagrams.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/25", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-25", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "section_divider", "function": "transition", "notes": "The slide uses a human-centric approach to introduce a strategic section.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/26", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-26", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "segmentation", "function": "present_solution", "notes": "The slide uses a pyramid to segment the market by patient need and product modality.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/27", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-27", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "key_messages", "function": "present_solution", "notes": "Uses a pictograph to represent patient population segments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/28", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-28", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "key_takeaways", "function": "quantify_opportunity", "notes": "The chart shows a comparison of branded vs unbranded/off-label market size over time, and a pie chart showing patient source.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/29", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-29", "loopMatches": [ { "to": 29, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142", "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space", "position": 2, "objective": "What are the key opportunities for AstraZeneca's Rare Disease division", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 29, "from": 20, "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "key_messages", "function": "size_opportunity", "notes": "The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/30", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-30", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "kpi_overview", "function": "present_framework", "notes": "The slide uses a matrix layout to map drug assets against biological targets and development status (marketed, late-stage, early-stage, preclinical).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/31", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-31", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "section_divider", "function": "transition", "notes": "The slide uses a high-emotion photo of a father and son to humanize the medical topic.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/32", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-32", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a matrix-like layout to map drug assets against therapeutic areas and development status.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/33", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-33", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "problem_statement", "function": "diagnose_problem", "notes": "Includes a visual representation of the metabolic pathway and radiographic evidence of treatment efficacy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/34", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-34", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "propose_solution", "function": "size_opportunity", "notes": "The slide uses a Venn-style diagram to illustrate market expansion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/35", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-35", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "problem_statement", "function": "diagnose_problem", "notes": "The slide uses a process diagram to illustrate the pathophysiology of two distinct types of amyloidosis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/36", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-36", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a comparative structure to map assets to specific disease indications and their clinical progress.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/37", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-37", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "propose_solution", "function": "present_solution", "notes": "The slide uses a process flow for the trial design and a table for disease staging and median overall survival (OS).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/38", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-38", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "key_messages", "function": "summarize", "notes": "The slide uses a matrix-like layout to categorize drugs by disease area and development stage (marketed, late-stage, early-stage).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/39", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-39", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "section_divider", "function": "transition", "notes": "The slide uses a circular overlay on a stock photo of a business meeting.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/40", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-40", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "geographic_map", "function": "size_opportunity", "notes": "The slide uses a timeline-based map visualization to illustrate market penetration goals.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/41", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-41", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "key_takeaways", "function": "size_opportunity", "notes": "The slide uses a map to anchor the geographic focus and a table to list specific drug approvals by disease category.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/42", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-42", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/43", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-43", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "key_messages", "function": "present_solution", "notes": "The slide uses a bridge metaphor to represent the collaboration between the two entities.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/44", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-44", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "key_messages", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/45", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-45", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 46, "slideType": "section_divider", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/46", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-46", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/47", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-47", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 48, "slideType": "other", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/48", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-48", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac", "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 49, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/49", "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac", "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-49", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 30, "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7cac-75f7-8c4d-c1df42c29745", "docSlug": "674201d8cef93b1820f78aa5772cd90f", "documentTitle": "ATAI | Investor Presentation Deck | 36 slides", "authorId": "atai", "authorName": "atai Life Sciences", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/709ZroXsz_t5XiFjdoXd2K25RohDXj87ck0-q4_RSAk/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82NzQyMDFkOGNlZjkzYjE4MjBmNzhhYTU3NzJjZDkwZi9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/1", "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745", "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/K-7ygRjt6WJxLQU8smGHmzgGOsoBkZOb8guIsUy2tTs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82NzQyMDFkOGNlZjkzYjE4MjBmNzhhYTU3NzJjZDkwZi9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/AEKaGtHYI64OFQMYOqGQAGDrdBMWd5HQSxJc5ytRGlM/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82NzQyMDFkOGNlZjkzYjE4MjBmNzhhYTU3NzJjZDkwZi9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/Sx9ePLqn9UA5cJaEkrXXvZ23V1JzAKML3YNbfgwt1-A/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82NzQyMDFkOGNlZjkzYjE4MjBmNzhhYTU3NzJjZDkwZi9wMDAxLnBuZw" }, { "docId": "019de073-7cac-75f7-8c4d-c1df42c29745", "docSlug": "674201d8cef93b1820f78aa5772cd90f", "documentTitle": "ATAI | Investor Presentation Deck | 36 slides", "authorId": "atai", "authorName": "atai Life Sciences", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": "Includes a specific date note at the bottom: September 9th, 2022.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/2", "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745", "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7cac-75f7-8c4d-c1df42c29745", "docSlug": "674201d8cef93b1820f78aa5772cd90f", "documentTitle": "ATAI | Investor Presentation Deck | 36 slides", "authorId": "atai", "authorName": "atai Life Sciences", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a numbered list to present key company highlights.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/3", "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745", "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7cac-75f7-8c4d-c1df42c29745", "docSlug": "674201d8cef93b1820f78aa5772cd90f", "documentTitle": "ATAI | Investor Presentation Deck | 36 slides", "authorId": "atai", "authorName": "atai Life Sciences", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "team_bio", "function": "other", "notes": "The slide uses a combination of headshots for the team and a metric-based footer to establish credibility.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/4", "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745", "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 4, "beatId": "2ffc34b8-f626-46ac-ba6a-a6eaba9e2035", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "Slide 4 presents team bio", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7cac-75f7-8c4d-c1df42c29745", "docSlug": "674201d8cef93b1820f78aa5772cd90f", "documentTitle": "ATAI | Investor Presentation Deck | 36 slides", "authorId": "atai", "authorName": "atai Life Sciences", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a hierarchical structure to connect a high-level objective to three distinct operational pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/5", "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745", "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-5", "loopMatches": [ { "to": 8, "from": 5, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "a52ea986-ebcf-42a8-9f02-0ec1a9a29f05", "evidence": "Slides 5-8 present the solution and pipeline", "position": 1, "objective": "Present the solution and pipeline overview", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 5, "from": 5, "beatId": "1f98bed8-0bf2-4839-9c4b-654cf1087c44", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slide 5 presents the solution overview", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7cac-75f7-8c4d-c1df42c29745", "docSlug": "674201d8cef93b1820f78aa5772cd90f", "documentTitle": "ATAI | Investor Presentation Deck | 36 slides", "authorId": "atai", "authorName": "atai Life Sciences", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a Gantt-style visualization to show progress through Preclinical, Phase 1, and Phase 2 stages for multiple assets.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/6", "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745", "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-6", "loopMatches": [ { "to": 8, "from": 5, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "a52ea986-ebcf-42a8-9f02-0ec1a9a29f05", "evidence": "Slides 5-8 present the solution and pipeline", "position": 1, "objective": "Present the solution and pipeline overview", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7cac-75f7-8c4d-c1df42c29745", "docSlug": "674201d8cef93b1820f78aa5772cd90f", "documentTitle": "ATAI | Investor Presentation Deck | 36 slides", "authorId": "atai", "authorName": "atai Life Sciences", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a hub-and-spoke diagram to represent the platform model.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/7", "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745", "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-7", "loopMatches": [ { "to": 8, "from": 5, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "a52ea986-ebcf-42a8-9f02-0ec1a9a29f05", "evidence": "Slides 5-8 present the solution and pipeline", "position": 1, "objective": "Present the solution and pipeline overview", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-7cac-75f7-8c4d-c1df42c29745", "docSlug": "674201d8cef93b1820f78aa5772cd90f", "documentTitle": "ATAI | Investor Presentation Deck | 36 slides", "authorId": "atai", "authorName": "atai Life Sciences", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "timeline", "function": "plan_implementation", "notes": "The slide uses a horizontal arrow timeline for future catalysts and a vertical list for past milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/8", "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745", "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-8", "loopMatches": [ { "to": 8, "from": 5, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "a52ea986-ebcf-42a8-9f02-0ec1a9a29f05", "evidence": "Slides 5-8 present the solution and pipeline", "position": 1, "objective": "Present the solution and pipeline overview", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }